Quercis Pharma AG is a private Swiss biotech company advancing a novel antithrombotic in multiple indications: the lead program is prevention of Venous Thrombosis Embolism in advanced cancer patients (phase III) followed by clinical trials in Sickle Cell Disease (phase II) and Covid-19 (phase II).
Products, services, technology
Quercis' drug candidate is a an isoquercetin-based formulation that prevents platelet activation and initiation of the thrombotic cascade without increasing the risk of bleeding.
Cooperation possibilities
Quercis is open for licensing partnerships.
- https://www.quercis.com/
- +41 79 500 36 83
- ilaeber@quercis.com
- Ilias Läber
